(UroToday.com) The bladder cancer non-invasive session at the American Urological Association, (AUA) included a presentation by Dr. Anirban Mitra discussing the impact of anti-adenoviral antibody levels for predicting nadofaragene firadenovec response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Nadofaragene firadenovec is a recombinant adenoviral vector-based intravesical therapeutic that delivers a copy of human IFNa2b gene to urothelial cells. The recent phase 3 trial in high-grade BCG-unresponsive NMIBC reported a 60% complete response rate in the efficacy population at 3 months, and this response was maintained in 51% of patients at 12 months.1 This analysis examined the value of anti-adenoviral antibody level as a predictor of therapeutic response in patients receiving nadofaragene firadenovec.